Comparative effectiveness of baricitinib and alternative biological DMARDs in a Swiss cohort study of patients with RA.
Benoit Thomas P GilbertDenis MonginRomain AymonKim LauperCédric LaedermannClémentine PerrierRuediger MuellerDelphine Sophie CourvoisierAxel FinckhPublished in: BMJ open (2024)
BARI demonstrated a significantly higher drug maintenance compared with TNFi, mainly due to lower drug discontinuations for ineffectiveness. We found no difference in drug maintenance between BARI and OMA. Clinical outcomes did not differ between the three groups. Our results suggest that BARI is an appropriate therapeutic alternative to bDMARDs in the management of RA.